What question did this study set out to answer?

To evaluate the efficacy and safety of amifampridine in combination with pyridostigmine in patients with AChRAb+ myasthenia gravis.

April 10, 2026

Efficacy and Safety of Amifampridine in Myasthenia Gravis

Key Points

To evaluate the efficacy and safety of amifampridine in combination with pyridostigmine in patients with AChRAb+ myasthenia gravis.
Conducted a clinical trial comparing amifampridine plus pyridostigmine to pyridostigmine alone.
Measured treatment outcomes including efficacy and adverse events.
Focused on patients diagnosed with AChRAb+ myasthenia gravis.
Combining amifampridine with pyridostigmine was not more effective than pyridostigmine alone.
Patients receiving amifampridine experienced more adverse events compared to those on pyridostigmine only.

Abstract

This study provides Class I evidence that in patients with AChRAb+ MG, the addition of amifampridine to pyridostigmine was not superior to treatment with pyridostigmine alone and was associated with a higher incidence of adverse events.

Bookmark

Cite This Study

Remijn-Nelissen et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8946e6c1944d70ce055eb https://doi.org/https://doi.org/10.1212/wnl.0000000000214715

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark